Ignite Creation Date:
2024-05-06 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05727904
Status:
RECRUITING
Last Update Posted:
2024-07-08
First Post:
2023-02-06
Brief Title:
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma
Sponsor:
Iovance Biotherapeutics Inc
Organization:
Iovance Biotherapeutics Inc
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Metastatic Melanoma |
| Unresectable Melanoma |
| Melanoma |
Keywords:
| Name | View |
|---|---|
| TILVANCE-301 | View |
| Tumor Infiltrating Lymphocytes | View |
| TIL | View |
| Metastatic Melanoma | View |
| Unresectable Melanoma | View |
| Cell Therapy | View |
| Cellular Immuno-therapy | View |
| IL-2 | View |
| Non-myeloablative lymphodepletion NMALD | View |
| Check point inhibitor | View |
| Melanoma | View |
| Lifileucel | View |
| Stage III Melanoma | View |
| Stage IV Melanoma | View |
| Skin cancer | View |
| Skin cancer types | View |
| Malignant melanoma | View |
| Autologous Adoptive Cell Therapy | View |
| Autologous Adoptive Cell Transfer | View |
| LN-144 | View |
| Pembrolizumab | View |
| Pembro | View |
| AdjuvantNeo-adjuvant | View |
| BRAFMEK | View |
| ICI | View |
| BRAF v600 | View |
| Immune checkpoint inhibitor | View |
| Tumor infiltrating T-cells | View |
| TILVANCE | View |